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INTRODUCTION  
Poorly water-soluble drugs exhibit many difficu lties in  
the development of pharmaceutical dosage forms due to 
their limited water solubility, slow dissolution rate and 
low bioavailability
1
. Nowadays, pharmaceutical 
technology provides many approaches to enhance the 
dissolution rate of poorly soluble drugs. Physical 
modifications often aim to increase the surface area, 
solubility and/or wettability of the powder part icles and 
are therefore focused on particle size reduction or 
generation of amorphous states  
2
. There are many ways to 
increase the aqueous solubility of such compounds, 
including micronization, salt formation and formulat ion 
of the drug as a solid dispersion (SD). For many 
compounds, however, decreasing the particle size may  
not lead to a significant or adequate increase in  
bioavailability. Salt formation may also be problemat ic, 
particularly with neutral compounds and weak acids . 
Solid dispersion involves at least two different solid 
components, generally a hydrophilic matrix and a 
hydrophobic drug; the matrix can be either crystalline or 
amorphous. The drug can be dispersed molecularly, in  
amorphous particles (clusters) or in crystalline part icles 
3
. 
Solid dispersion method has been widely employed to 
improve the dissolution rate, solubility and oral 
absorption of poorly water soluble drugs
 4-5
. Numerous 
solid dispersion systems have been demonstrated in the 
pharmaceutical literature along with various hydrophilic 
carriers, such as polyethylene glycols, 
polyvinylpyrrolidone, hydroxypropyl methylcellu lose, 
gums, sugar, mannitol and urea 
6
. 
Spironolactone (SPN) is K
+
- sparing diuret ics, an 
antagonist of aldosterone, a mineralocortico id, competing 
for intracellular aldosterone receptors in the cells of the 
distal tubule 
7
. It is used in the treatment of primary  
hyperaldosteronism (adrenal adenomas or b ilateral 
adrenal hyperplasia) and or refractory edema associated 
with secondary aldosteronism (cardiac failure, hepatic 
cirrhosis, nephritic syndrome and severe ascites). 
Spironolactone added to standard therapy substantially  
reduces morbidity and mortality and ventricular 
arrhythmias in patient with heart failure 
8
.   
The objective of this work was to investigate the 
improvement in the aqueous solubility and dissolution 
rate of spironolactone by preparing solid  dispersion with 
various polymers such as poloxomer 407, ko llicoat IR, 
kollidon VA 64 and polyethylene glycol 6000 (PEG 
6000). 
Dissolution data were compared by using both model 
dependant (Zero order model, First order, Hixson-
Crowell cube root law and Higuchi square root law) and 
model independent (difference factor (f1), similarity 
factor (f2), dissolution efficiency (%DE) and mult iple 
comparison Bonferroni test) 
9-14
. 
MATERIALS AND METHODS  
Spironolactone was collected from Incepta 
Pharmaceuticals Ltd, Bangladesh. Poloxamer 407 (BASF, 
Germany) ko llicoat IR(BASF, Germany),  ko llidon VA 64 
(BASF, Germany) and PEG 6000 (LOBA India) were 
procured from commercial sources. All other chemicals 
and reagents used in this study were of analytical grade.  
Preparation of solid dispersion 
Solid Dispersions of spironolactone in Poloxomer 407, 
Kollicoat IR, Kollidon VA 64 and PEG 6000 in different 
weight ratios (1:5, 1:10, 1:15 and 1:20) were prepared by 
ABSTRACT:  
In this study binary and ternary solid dispersions (SDs) of spironolactone were prepared by solvent evaporation technique using 
Poloxamer 407,  kollicoat IR, kollidon VA 64 and PEG 6000 as carrier. In binary solid dispersion drug –carrier weight ratio was 
1:5, 1:10, 1:15 and 1:20. In ternary solid dispersions drug was dispersed with mixture of PEG 6000 and Kollidon  VA 64 in the 
ratio 1/2/10, 1/3/10, 1/4/10, 1/5/10. The solid dispersions were investigated for drug loading and dissolution behavior. Solid 
dispersions were found effective to enhance the solubility of spironolactone in water significantly. Evaluation of the properties 
of the SDs was also performed by using Fourier-transform infrared (FTIR) spectroscopy and X-ray diffraction (XRD) studies. 
The FTIR spectroscopic studies showed the stability of spironolactone and absence of well-defined spironolactone -poloxomer 
407 interaction. The XRD studies indicated the amorphous state of spironolactone in SDs of spironolactone with poloxomer 
407. Dissolution data of SDs were compared by using both model dependant and model independent technique. No significant 
difference in % DE (dissolution efficiency) was found among the ternary SDs. But in case of binary SDs drug release was found 
to depend on the nature and amount of carrier. So, Solid dispersion technique may be an effective technique to enhance 
dissolution rate of spironolactone.  
Key words: Spironolactone. PEG 6000, solid dispersion, poorly water soluble, Poloxamer 407  
 
Islam et al                                 Journal of Drug Delivery & Therapeutics; 2012, 2(4), 73-80    74 
© 2011, JDDT. All Rights Reserved                                           ISSN: 2250-1177                                          CODEN (USA): JDDTAO 
solvent evaporation method and denoted as POL, KIR, 
KVA and PEG 1/5, 1/10, 1/15, 1/20 respectively. 
Spironolactone was dissolved in sufficient amount of 
acetone and the carrier was added. The solvent was then 
completely evaporated at 40-45º C and the resulting 
residue was dried under vacuum for 3 h, stored in  
desiccators at least overnight, ground in a mortar, and 
passed through a #100 sieve. 
Ternary solid dispersion using mixture of polymer was 
also prepared in the same way.  PEG 6000 (less effective 
carrier in case of binary solid dispersion) was mixed with 
Kollidon VA 64 (highest effective carrier in case of 
binary solid dispersion) in the ratio  1/2/10, 1/3/10, 1/4/10, 
1/5/10(Drug/ Peg 6000/  Kollidon VA 64 ) and denoted as 
PKVA 1/2/10, 1/3/10, 1/4/10, 1/5/10.  
Determination of drug content in solid dispersions 
To determine the potency SD equivalent to 10 mg 
spironolactone was taken and dissolved in 100 ml 
methanol as per assay method described in BP for 
spironolactone tablet
15
. Then the solution was filtered  and 
assayed by Shimadzu UV/Visible double beam 
spectrophotometer at 238 nm. Finally the amount of drug 
in each formulation was calcu lated. 
In Vitro Dissolution Data 
The in-vitro dissolution tests were performed for the pure 
spironolactone and solid dispersions, using USP 
dissolution test apparatus type II (paddle type) using 900 
ml of purified water as dissolution medium. As the drug 
is practically insoluble in water as mentioned in BP
15
, we 
used this media to compare the dissolution profile o f pure 
drug with that of prepared b inary and ternary solid  
dispersion. The temperature of the medium was 
maintained at 37
0
C±0.5
o
C throughout the experiment. 
The samples containing 25 mg of spironolactone or its 
equivalent solid dispersions were placed in the dissolution 
medium. Paddle was used at a stirring rate of 75 rpm. A  
10 ml aliquot was withdrawn at predetermined time 
intervals of at 10, 20, 30, 40, 50 and 60 minutes and then 
10 ml of fresh dissolution medium was rep laced to 
maintain the constant volume of dissolution medium. 
From the samples collected, 1 ml was diluted with 
dissolution medium and the absorbance of the diluted 
solutions were measured at 238 nm using Shimadzu  
UV/Visib le double beam spectrophotometer (Shimadzu, 
Japan) against dissolution medium as blank. Percentage 
of drug release was calcu lated using the equation 
obtained from the standard curve prepared in the media.  
Comparison of dissolution data by Model Dependent 
Methods  
To study the release kinetics, data obtained form in vitro  
drug release study were tested with the following 
mathematical model. 
Zero order equation  
The equation assumes that the cumulative amount of d rug 
release is d irectly  related to time. The equation may  be as 
follows: 
C = K0 t--------------------- (1) 
Where, K0 is the zero o rder rate constant expressed in unit 
concentration/time and t is time. A graph of concentration 
vs time would y ield  a straight line with a slope equal to 
K0 and intercept the origin of the axes.  
 First order equation 
The release behavior of first order equation is expressed 
as log cumulative percentage of drug remaining vs time. 
The equation may be as follows
16:
 
Log C = Log C0 - kt / 2.303 ----------------------------- (2) 
Where,  
C  =  The amount of drug un-dissolved at t time,  
C0  = Drug concentration at t = 0,  
k   =  Corresponding release rate constant. 
Higuchi square root law  
The Higuchi release model describes the cumulative 
percentage of drug release vs square root of time. The 
equation may be as follows 
17
: 
Q = K√t        ----------------------------------------- (3)  
Where, Q = the amount of drug dissolved at time t. K is 
the constant reflecting the design variables of the system. 
Hence, drug release rate is proportional to the reciprocal 
of the square root of time. 
 Hixson-Crowell cube root law  
It is the law that represents idea about the evaluation of 
drug release pattern changes with the surface area and the 
diameter of the particles
18
. It is mentioned as the cube 
root of the percentage of drug remain ing in the matrix vs 
time. The equation is as follows 
Q0
1/3 – Qt
1/3 
= kHC х t-------------------------------- (4)  
Where, 
Q0  = Init ial amount of the drug in the tablets 
Qt = The amount of drug release in time t  
kHC  =  The rate constant for the Hixson-Crowell 
cube root law 
Comparison of dissolution data by Model Independent 
Methods  
Data obtained form in v itro drug release study were tested 
with the different model independent technique 
(dissolution efficiency (%DE) difference factor (f1), 
similarity factor (f2), and multiple comparison Bonferroni 
test) 
Dissolution efficiency (%DE) was employed to compare 
the drug release from d ifferent solid dispersion. 
Dissolution efficiency is the area under the dissolution 
curve within  a time range (t1 - t2) expressed as a 
percentage of the dissolution curve at maximum 
dissolution, over the same time frame
19
. This was 
calculated from the equation: 
 
Where y is the percentage dissolved at time t  
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Difference factor (f1) and similarity factor (f2) were 
calculated to find out similarity of solid  dispersion.  
Difference factor f1 is the percentage difference between 
two curves at each point and is a measurement of the 
relative error between  the two curves. The similarity 
factor (f2) is a logarithmic reciprocal square root 
transformation of the sum of squared error and is a 
measurement of the similarity in  the percent (%) 
dissolution between the two curves. The following 
equations were used to calculate difference factor f1 and 
similarity factor f2: 
 
 
Where n is the number of time points, Rt is the 
dissolution value of reference product at time t and Tt is 
the dissolution value for the test product at time t.  
Similarity factor f2 has been adopted by FDA (1997) and 
the European Agency for the Evaluation of Medicinal 
Products (EMEA, 2001) by the Committee for 
Proprietary Medicinal Products (CPMP) to compare 
dissolution profile 
20-22
. Two dissolution profiles are 
considered similar and bioequivalent, if f1 is between 0 
and 15 and f2 is between 50 and 100 (FDA, 1997).  
Multiple comparison techniques provide a detail picture 
of exact ly which treatments differ from one another. We 
used Bonferroni test, most commonly used post hoc test, 
to find out the holmologous group with in ternary SDs. 
SPSS version 12.0 is used to perform the test. 
Fourier-Transform Infrared S pectroscopy 
Fourier-transform infrared (FT-IR) spectra were obtained 
by using an FT-IR spectrometer-430 (Jasco, Japan). The 
samples (spironolactone or SDs) were prev iously ground 
and mixed thoroughly with potassium bromide, an  
infrared transparent matrix, at 1:5 (Sample: KBr) ratio, 
respectively. The KBr discs were p repared by 
compressing the powder at a pressure of 5 tons for 5 min  
in a hydraulic press. Scans were obtained at a  resolution 
of 4 cm-1, from 4000 to 500 cm-1. 
X-ray diffraction 
X-ray powder d iffraction patterns were obtained at room 
temperature using a D 8 ADVANCE X-ray diffractometer 
(BRUKER, Germany) with Cu as anode material and 
graphite monochromator, operated at a voltage of 35 kV 
and 20 mA current. The samples were analysed in the 2θ 
angle range of 5°–70° and the process parameters were 
set as: scan step size of 0.02° (2θ), and scan step time of 
0.5 degree/min. 
RES ULTS AND DISCUSS ION  
Physical appearance  and Potency of prepared solid 
dis persion  
The spironolactone solid dispersions were prepared  
employing solvent evaporation method. All solid  
dispersions were white fine powders. No d iscoloration 
was observed during preparation of SD. Prior to in-vitro  
dissolution study the prepared solid  dispersion was 
subjected to potency test. Three measurements were 
performed and Potency ± SD of different SD with pure 
drug is shown in table1. Potency of spironolactone was 
between 95-101%.  
Table 1: Potency of pure drug and prepared SDs 
Sl. No. Item % Potency ± SD (n=3) 
1 Pure Drug 100.25±0.21 
2 POL1/5 99.25±0.34 
3 POL1 /10 99.75±0.42 
4 POL1 /15 100.2±0.51 
5 POL1 /20 95.25±0.28 
6 KVA1/5 96.75±0.35 
7 KVA1 /10 100.25±0.13 
8 KVA1 /15 97.25±0.54 
9 KVA1 /20 99.35±0.45 
10 PEG 1/5 98.57±0.66 
11 PEG 1/10 99.25±0.64 
12 PEG 1/15 99.35±0.65 
13 PEG 1/20 100.57±0.75 
14 KIR 1/5 96.65±0.75 
15 KIR 1/10 100.18±0.81 
16 KIR 1/15 97.62±0.85 
17 KIR 1/20 99.49±0.92 
18 PKVA 1/2/10 99.55±0.95 
19 PKVA1/ 3/10 99.85±0.12 
20 PKVA1/4/10 100.03±1.05 
21 PKVA1/5/10 99.52±0.62 
 
Dissolution profile of S pironolactone from binary 
Solid Dispersion 
 Binary Solid Dispersion of spironolactone was prepared 
with Poloxomer 407, Kollicoat IR, Kollidon VA 64 and 
PEG 6000 in d ifferent weight rat ios (1:5, 1:10, 1:15 and 
1:20). Drug releases from these solid dispersions are 
shown in figure 1-4.  
 
Figure 1: Average % drug release (n=6) from SD 
containing Poloxomer 407 
Drug release from pure drug powder was very slow.  
Only 7% drug was released within 5 minutes. Drug 
release was increased with time but finally only 48.31% 
drug was released after one hour.  
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Figure 2: Average % drug release (n=6) from SD 
containing Kollidon VA 64 
In vitro  dissolution studies indicate that drug release from 
SDs was faster from their pure drug. Drug release from 
SDs was found to depend on the nature and amount of 
carrier. 
 
Figure 3: Average % drug re lease (n=6) from SD 
containing Kollicoat IR 
Figure 1-4 show the in  vitro  release profile of 
spironolactone from SDs containing various carriers in  
different ratio. The percent release of spironolactone was 
found to be increased proportionately with the gradual 
increase in  the amount of carrier (Poloxomer 407, 
Kollicoat IR, Kollidon VA 64). The improvement in  the 
in vit ro drug release profile may be due to the reduction 
of particle size o f spironolactone and hence improving 
drug wettability and significantly better dissolution. With 
5 minutes 60-80% drug was released from solid  
dispersion containing Poloxomer 407, Kollicoat IR, 
Kollidon VA 64. About 10 fo ld increase of drug release 
was found in this formulation.  
 
Figure 4: Average % drug release (n=6) from SD 
containing PEG 6000 
Solid dispersion containing PEG 6000 also improves the 
dissolution rate of spironolactone than that of the pure 
drug due to its hydrophilic nature (Figure 4). As the 
relative proportion of PEG 6000 increased, 
spironolactone dissolution rates rose up to an extent after 
that dropped which could be attributed to the localizat ion 
of higher amounts of carrier itself.  
Dissolution profile of S pironolactone from Ternary 
Solid Dispersion 
Ternary Solid Dispersion of spironolactone was prepared 
with mixture o f Kollidon VA 64 and PEG 6000 in  
different weight ratios.  
 
Figure 5: % drug release from SD containing PEG 6000 
and Kollidon VA 64 
Ternary solid dispersions were found more effective to 
increase the dissolution rate than binary solid dispersion. 
Figure 5 shows the release profile of spironolactone from 
SD containing both PEG 6000 and kollidon VA 64. The 
amount of ko llidon VA 64 was kept constant however, 
the percentage of PEG 6000 changed gradually (15.38%, 
21.48% 26.66% and 31.25%) respectively. The 
formulat ion containing lowest amount of PEG 6000 
showed maximum drug release rate (100.23% after one 
hour) whereas other formulat ion containing more amount 
of PEG 6000 released less amount of drug that could be 
attributed to the localizat ion of higher amounts of carrier 
itself. 
Drug release kinetics 
In this study total 16 b inary SDs and 4 ternary SDs were 
prepared by solvent evaporation method. dispersion 
containing 1/5 drug polymer ratio were analyzed by Zero 
order model, First order, Hixson-Crowell cube root law 
and Higuchi square root equation as example. Y-equation 
(Y = aX+b) and correlat ion co-efficient (R
2
) of selected 
binary solid d ispersion and all ternary  solid d ispersion are 
shown in Figure 4 .The data shows that only pure drug 
follows 1
st
 order, Higuchi release model but in case of 
SDs, R
2 
 values were less than 0.693(Table 2). This may  
be due to the slow release rate of pure drug and higher 
release rate of SDs. 
On the other hand all the ternary solid  dispersions along 
with the respective mother binary SD (KVA 1/10) were 
analyzed with the same model. Y-equation (Y = aX+b) 
and correlation co-efficient (R
2
) of ternary solid  
dispersion are shown in table 3.The data shows that none 
follows the model. Th is may be due to the higher drug 
release rate from the ternary SDs. 
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Table 2: Y-equation (Y = aX+b) and correlat ion co-efficient (R
2
) from different plots of selected binary SDs  
Item Zero Order 1st Order Higuchi Model Hixson-Crowell Model 
Y equation R2 Y equation R2 Y equation R2 Y equation R2 
POL1/5 y = 0.814x + 45.38 0.39 y = -0.008x + 1.678 0.599 y = 8.831x + 27.72 0.664 y = 0.037x + 2.735 0.272 
KVA1/5 y = 0.931x + 47.47 0.425 y = -0.012x + 1.648 0.693 y = 9.971x + 27.82 0.704 y = 0.039x + 2.774 0.287 
KIR 1/5 y = 0.910x + 49.46 0.399 y = -0.013x + 1.622 0.689 y = 9.859x + 29.79 0.677 y = 0.767x + 2.042 0.515 
Pure Drug y = 0.760x + 8.313 0.865 y = -0.004x + 1.965 0.917 y = 6.662x - 1.557 0.961 y = 0.043x + 1.561 0.577 
 
Table 3: Y-equation (Y = aX+b) and correlat ion co-efficient (R
2
) from different plots of selected ternary SDs 
Item Zero Order 1st Order Higuchi Model Hixson-Crowell Model 
Y equation R2 Y equation R2 Y equation R2 Y equation R2 
KVA1 /10 y = 0.939x + 49.22 0.413 y = -0.014x + 1.626 0.714 y = 10.11x + 29.17 0.693 y = 0.039x + 2.808 0.282 
PKVA 1/2/10 y = 0.914x + 59.20 0.322 y = -0.025x + 1.432 0.794 y = 10.32x + 37.69 0.594 y = 0.038x + 2.987 0.251 
PKVA1/ 3/10 y = 0.849x + 61.08 0.279 y = -0.020x + 1.340 0.657 y = 9.857x + 39.98 0.543 y = 0.037x + 3.019 0.237 
PKVA1/4/10 y = 0.828x + 62.55 0.26 y = -0.020x + 1.250 0.589 y = 9.759x + 41.38 0.521 y = 0.037x + 3.042 0.231 
PKVA1/5/10 y = 0.820x + 61.06 0.265 y = -0.016x + 1.321 0.529 y = 9.619x + 40.27 0.527 y = 0.037x + 3.018 0.232 
  
Model independent analysis of dissolution data 
% DE indicates the overall performance of the carrier in  
drug release. % DE of all the prepared SDs along with 
pure drug were calculated (n=6) and shown in  table 4. The 
results indicate that ternary solid dispersion is more 
effective to increase the dissolution rate as % DE is more 
than 90%. On the other hand, in  binary solid dispersion 
dissolution efficiency was found to depend on the nature of 
polymer. % DE of KIR 1/5, KVA 1/10, KVA1 /15, KVA1 
/20 were found higher in case of 1/5, 1/10, 1/15 and 1/20 
drug-carrier rat io respectively. 
Table 4: Dissolution efficiencies (%DE) of SDs 
Sl. No. Item % DE (n=6) 
1 Pure Drug 32.97±0.95 
2 PEG 1/5 59.47±1.12 
3 POL1/5 73.59±1.05 
4 POL1 /15 74.95±2.62 
5 POL1 /10 75.62±1.28 
6 PEG1 /20 77.01±0.95 
7 POL1 /20 79.27±0.83 
8 KVA1/5 79.96±0.74 
9 KIR 1/5 81.23±1.45 
10 PEG 1 /10 81.98±2.66 
11 KIR 1/10 83.91±1.64 
12 KIR 1/15 84.43±2.65 
13 PEG1 /15 84.52±1.75 
14 KVA 1/10 84.76±2.75 
15 KIR 1/20 86.16±1.75 
16 KVA1 /15 87.38±2.75 
17 PKVA1/5/10 90.29±0.81 
18 PKVA1/ 3/10 91.35±1.85 
19 PKVA 1/2/10 91.55±3.12 
20 PKVA1/4/10 92.25±2.65 
21 KVA1 /20 94.35±1.75 
 
Percent drug release of SDs of 1/5 drug-carrier rat io was 
compared by difference factor (f1) and similarity factor 
(f2). POL 1/5 was used as reference to  calculate the f1 and 
f2 as %DE of POL 1/5 were more than PEG 1/% but less 
than KIR 1/5 and KVA 1/5. Table 5 shows the f1, f2 
values of different solid dispersion in respect of POL 1/5 
as a reference. Here different polymer with same drug 
polymer ratio was used for comparison. For KVA1/5 and 
KIR 1/5, f2 were more than 50 and f1 were less than 15. 
So they are similar with  the reference. But pure drug and 
PEG 1/5 are not similar with the reference. 
Table 5: Calculated difference factor ( f1) and similarity 
factor (f2) of b inary SDs 
Solid Dispersion f2 f1 
POL1/5 100.00 0.00 
KVA1/5 58.55 8.20 
KIR 1/5 55.57 9.85 
PEG 1/5 38.18 21.75 
Pure Drug 17.10 59.37 
 
Table 6 shows the f1, f2 values of different ternary solid 
dispersion in respect of PKVA 1/2/10 as a reference. KVA 
1/10 is the mother binary SDs for all the prepared ternary  
SDs, so it was also included for the comparison. For all the 
ternary solid d ispersion, f2 were more than 50 and f1 were 
less than 15. So, all the ternary  SDs is similar in respect of 
drug release. But binary SD, KVA 1/10 is not similar with 
the reference ternary SD (f2 = 46.54).  
The findings can also be proved by multiple comparison 
Bonferron i test. SPSS version 12.0 was used for mult iple 
comparisons. % DE at 60 min time of different SDs was 
used for this comparison. No significant difference was 
found among the ternary SDs. But mean difference of 
binary SD, KVA 1/10 and reference was significant at the 
.05 level. (Table 7) 
Table 6: Calculated difference factor ( f1) and similarity 
factor (f2) of ternary SDs 
time f2 f1 
PKVA 1/2/10 100.00 0.00 
KVA1 /10 46.54 11.62 
PKVA1/ 3/10 78.93 2.17 
PKVA1/4/10 72.51 2.39 
PKVA1/5/10 75.95 2.94 
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Table 7: mult iple comparison Bonferroni test result 
R-SD T-SD Mean Difference (R-T) Std. Error Sig. 95% Confidence Interval 
Lower Bound Upper Bound 
PKVA 1/2/10 KVA1 /10 9.57000(*) 0.500 0.000 7.993 11.147 
PKVA 1/2/10 PKVA1/ 3/10 0.200 0.500 1.000 -1.377 1.777 
PKVA 1/2/10 PKVA1/4/10 -0.700 0.500 1.000 -2.277 0.877 
PKVA 1/2/10 PKVA1/5/10 1.260 0.500 0.203 -0.317 2.837 
R-SD = References solid dispersion, T-SD = Test solid dispersion 
*  The mean difference is significant at the .05 level. 
 
Fourier-Transform Infrared S pectroscopy Study 
Fourier-transform infrared (FT-IR) spectroscopy was used 
to characterize possible interactions between the drug and 
the carrier in solid state. The IR spectrum of SD (POL 1/5) 
was compared with the standard spectrum of 
spironolactone. FT-IR spectra of spironolactone showed 
characteristic peaks at wave numbers 1768.75, 1680.99, 
1435.06, 1273.04, 1126.45cm
−1.
. Pure poloxomer 407 
showed characteristic peaks at wave numbers  3445.59, 
1663.63, 2887.49, 1466.87, 1350.19, 1448.61cm
−
1.SD of 
spironolactone with poloxomer 407 contains  characteristic 
peaks  of spironolactone(1768.75 45cm
−1
) and poloxomer 
(2887.49, 1465.93 45cm
−1
). A combine peak at (3442.03 
cm
−1
) was also observed. IR spectra of spironolactone and 
POL 1/5 are  shown in figure 6-7. From this study, it can be 
conclude that, there was no chemical interaction in this SD 
formulat ion. 
 
Figure 6: FTIR Spectrum of Sp ironolactone 
 
                                              Figure 7: IR spectrum of poloxomer 407 
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Figure 8: FTIR Spectrum of So lid Dispersion of Spironolactone (POL 1/5) 
X-ray diffractions (XRD) 
The solid state characterizat ion of drug and SD were 
investigated using XRD to find out crystalline nature of 
spironolactone and solid dispersion (POL 1/5) . The 
diffraction spectrum of pure spironolactone showed that 
the drug was crystalline in nature as it was demonstrated 
by numerous peaks. Numerous diffraction peaks of 
spironolactone were observed at 20 of 9.18, 16.66, 17.3, 
and 20.28 (Figure 9) indicating crystalline spironolactone. 
Some changes in the peak positions of spironolactone were 
observed in SDs (POL 1/5). The prominent peaks in the 
SD were 6.5, 11.44, 15.64, 20.6, and 21.72. Peak intensity 
was also decreased in SD. Highest peak intensity in case of 
pure spironolactone was 2010 counts, on the other hand it 
was only 1185 in case of SD.  
The relat ive reduction of d iffraction intensity of 
spironolactone in SD preparations at these angles suggests 
that the size of the crystals was reduced. The results of this 
study imply that spironolactone is present in partially  
amorphous or microcrystalline form in the SDs.  
 
Figure 9: X-ray d iffraction (XRD) patterns of Pure Spironolactone 
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Figure 10: X-ray diffraction (XRD) patterns of 1:5 o f Sp ironolactone and poloxomer 
CONCLUS ION 
Solid dispersions of spironolactone with different carriers 
in different ratios were prepared to imp rove dissolution 
characteristics. . Solvent evaporation method was 
employed to prepare solid dispersions. In vitro dissolution 
studies showed that solid dispersions of water insoluble 
drug with d ifferent carriers were effective in increasing the 
dissolution of spironolactone and gave greater release rate 
than pure drug. Dissolution data analyzed by model 
dependant and in dependant technique proves that binary 
SDs of poloxomer 407 is similar with IR, ko llidon VA 64. 
On the other hand, all ternary SDs were similar. But, 
binary SD (KVA 1/10) was not similar with the ternary  
SDs. So, ternary SDs is more effective to increase the 
spironolactone release rate. However, in vivo study is 
required for final select ion of carrier. 
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